Potential Anti-Inflammatory and Anti-Cancer Properties of Farnesol

Farnesol, an acyclic sesquiterpene alcohol, is predominantly found in essential oils of various plants in nature. It has been reported to exhibit anti-cancer and anti-inflammatory effects, and also alleviate allergic asthma, gliosis, and edema. In numerous tumor cell lines, farnesol can modulate var...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 23; no. 11; p. 2827
Main Authors Jung, Young Yun, Hwang, Sun Tae, Sethi, Gautam, Fan, Lu, Arfuso, Frank, Ahn, Kwang Seok
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 31.10.2018
MDPI
Subjects
Alzheimer's disease
Angiogenesis
Anti-oncogenes
Apoptosis
Asthma
Atherosclerosis
Breast cancer
cancer
Cancer therapies
Cell activation
Cell cycle
Cell growth
Cell proliferation
Chemokines
Cyclooxygenase-2
Cytokines
Edema
Essential oils
Farnesol
Genes
Gliosis
Infections
Inflammation
Inflammatory diseases
Interleukin 6
Kinases
Lung cancer
Lymphocytes B
Medical prognosis
Metastasis
Multiple myeloma
Nitric oxide
Nitric-oxide synthase
Prostate cancer
Proteins
Ras protein
Review
Signal transduction
Thyroid gland
Tumor cell lines
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Virulence
farnesol
apoptosis
cancer
inflammation
Online AccessGet full text

Cover

More Information
Summary:Farnesol, an acyclic sesquiterpene alcohol, is predominantly found in essential oils of various plants in nature. It has been reported to exhibit anti-cancer and anti-inflammatory effects, and also alleviate allergic asthma, gliosis, and edema. In numerous tumor cell lines, farnesol can modulate various tumorigenic proteins and/or modulates diverse signal transduction cascades. It can also induce apoptosis and downregulate cell proliferation, angiogenesis, and cell survival. To exert its anti-inflammatory/anti-oncogenic effects, farnesol can modulate Ras protein and nuclear factor kappa-light-chain-enhancer of activated B cells activation to downregulate the expression of various inflammatory mediators such as cyclooxygenase-2, inducible nitric oxide synthase, tumor necrosis factor alpha, and interleukin-6. In this review, we describe the potential mechanisms of action underlying the therapeutic effects of farnesol against cancers and inflammatory disorders. Furthermore, these findings support the clinical development of farnesol as a potential pharmacological agent in clinical studies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules23112827